Synthorx Inc. (THOR)
Symbol Info
Listed Symbol THOR
Name Synthorx Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-18.11
Price Info
21 Day Moving Average $16.3433
21 Day EMA $15.389130
50 Day Moving Average $16.7294
50 Day EMA $16.181700
200 Day EMA $15.862490
200 Day Moving Average 16.490050
52 Week High $23.53
52 Week Low $11.00
52 Week Change $
Alpha 0.000573
Beta -0.6281
Standard Deviation 0.205320
R2 0.016241
Periods 10
Share Information
10 Day Average Volume 106,864
20 Day Average Volume 95,562
30 Day Average Volume 75,268
50 Day Average Volume 62,200
Outstanding Shares 32,266,004
Float Shares 31,538,977
Percent Float 97.75%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 108
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 517,013
Institute Holdings Percent 74.000000
Institute Sold Previous 3 Months 767,935
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 8
Insider Holdings Percent 2.30%
Insider Sold Previous 3 Months -
Insiders Shares Owned 727,027
Price Change
7 Day Price Change $-0.2800007
7 Day Percent Change -2.10%
21 Day Price Change $-5.63
21 Day Percent Change -30.17%
30 Day Price Change $-5.9900007
30 Day Percent Change -31.49%
Month To Date Price Change $-3.24
Month To Date Percent -19.91%
90 Day Price Change $-2.93
90 Day Percent Change -18.36%
Quarter To Date $-3.240001
Quarter To Date Percent -19.91%
180 Day Price Change $-6.650001
180 Day Percent Change -33.79%
200 Day Price Change $-6.27
200 Day Percent Change -32.49%
Year To Date $-4.349999
Year To Date Percent -25.03%
Profile
Description Synthorx Inc is a biopharmaceutical company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. The company through its platform technology expands the genetic code by adding a new DNA base pair. Its lead product candidate includes THOR-707 a variant of IL-2 designed to kill tumor cells. It uses the Expanded Genetic Alphabet platform technology to develop cytokine Synthorins. It has designed cytokine Synthorin programs, including IL-2, IL-10 and IL-15, for the treatment of cancer, and another IL-2 Synthorin program for the treatment of autoimmune disorders.
Details
Issue Type CS
Market Cap $420,426,032
Sec Type
Auditor Ernst & Young LLP
Total Shares Outstanding 32,266,004
CEO Laura Shawver
Employees 38
Last Audit UQ
Classification
CIK 0001609727
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 11099 North Torrey Pines Road
Suite 190
La Jolla, CA 92037
Website https://www.synthorx.com
Facisimile
Telephone +1 858 750-4700
Email
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $363,010,885
Price To Sales -
Price To Free Cash -14
PE High Last 5 Years -
Price To Book 2.8
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 2.8
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 22.8
Leverage Ratio 1.0
Quick Ratio 22.3
Long Term Debt To Capital 0.02
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -42.47
Return On Equity -45.13
Return On Capital -44.26
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
THOR
Synthorx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.